All In Biotech

Free tool

FAERS Monitor: Exdensur

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761458 or its brand name (Exdensur, Depemokimab-Ulaa). Reports on generic versions are filed under their own applications.

Reports

79

Serious

31

39% of reports

Hospitalization

22

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • asthma13
  • chest pain6
  • dizziness5
  • dyspnoea5
  • headache5
  • cough4
  • pruritus4
  • rash4
  • arthralgia3
  • death3
  • drug ineffective3
  • fatigue3
  • influenza like illness3
  • injection site pain3
  • pain3

Reports by year received

View as table
YearReports
202312
20242
202665

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,080 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
asthmaSignal1330.618.6345
influenza like illnessSignal39.73.216
chest painSignal68.64.033
coughSignal43.81.56
pruritus42.81.13
dizziness52.71.14
injection site pain32.60.92
rash42.40.92
dyspnoea52.41.03
headache52.10.92
arthralgia31.90.61
pain31.30.40
fatigue31.00.30
death30.90.30
drug ineffective30.60.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.